Different roles of N- and C-termini in the functional activity of FGF21

Journal of Cellular Physiology

Volumn 219, Issue 2, 2009, Pages 227-234

  Micanovic, Radmila ^a   Raches, David W ^a   Dunbar, James D ^a   Driver, David A ^a   Bina, Holly A ^a   Dickinson, Craig D ^a   Kharitonenkov, Alexei ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BETA KLOTHO; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; GLUCOSE TRANSPORTER 1; KLB PROTEIN, MOUSE; MEMBRANE PROTEIN; SLC2A1 PROTEIN, MOUSE;

ADIPOCYTE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; ANIMAL; CELL STRAIN 3T3; CHEMISTRY; CYTOLOGY; FIBROBLAST; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

LOTUS;

3T3 CELLS; ADIPOCYTES; ANIMALS; APOPTOSIS; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; GLUCOSE TRANSPORTER TYPE 1; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FIBROBLAST GROWTH FACTOR; SURFACE PLASMON RESONANCE;

EID: 62149139387     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21675     Document Type: Article

References (39)

1. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M. 2008. FGF21 attenuates lipolysis in human adipocytes - A possible link to improved insulin sensitivity. FEBS Lett 582:1725-1730.
2. Badman MK, Pissios P, Kennedy A, Koukos G, Flier JS, Maratos-Flier E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437.
3. Berglund ED, Li CY, Bina HA, Lynes SG, Michael MD, Kharitonenkov A, Wasserman DH. 2008. FGF21 controls glycemia via regulation of tissue-specific glucose flux and insulin sensitivity. Submitted.
4. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. 2008. FGF21 corrects obesity in mice. Endocrinology 149:6018-6027.
5. Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, Papezová H, Haluzík M. 2008. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93:3627-3632.
6. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149.
7. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:2594-2603.
8. Fukumoto S. 2008. Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23. Intern Med 47:337-343.
9. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M. 2008. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab 8:169-174.
10. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS, Mohammadi M. 2007. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27:3417-3428.
11. Grose R, Dickson C. 2005. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179-186.
12. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J, Blundell TL. 2004. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 43:629-640.
13. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225.
14. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. 2007. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425.
15. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, Nabeshima YI. 2000. Molecular cloning and expression analyses of mouse beta klotho, which encodes a novel Klotho family protein. Mech Dev 98:115-119.
16. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. 2005. FGF21 as a novel metabolic regulator. J Clin Invest 115:1627-1635.
17. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. 2007. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781.
18. Kharitonenkov A, Shanafelt AB. 2008. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 22:37-44.
19. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, Ding L, Micanovic R, Mehrbod SF, Knierman MD, Hale JE, Coskun T, Shanafelt AB. 2008. FGF21/FGF21, receptor interaction and activation is determined by beta Klotho. J Cell Physiol 215:1-7.
20. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kuma E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51.
21. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. 2007. Tissue-specific expression of beta Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF21. J Biol Chem 282:26687-26695.
22. Kurosu H, Kuro-o M. 2008. The Klotho gene family and the endocrine fibroblast growth factors. Curr Opin Nephrol Hypertens 17:367-368.
23. Lundåsen T, Gälman C, Angelin B, Rudling M. 2006. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260:530-536.
24. Mohammadi M, Olsen SK, Ibrahimi OA. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16:107-137.
25. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A. 2007. Molecular determinants of FGF21 activity - Synergy and cross-talk with PPARgamma signaling. J Cell Physiol 210:1-6.
26. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK. 2008. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 74:403-412.
27. Nishimura T, Nakatake Y, Konishi M, Itoh N. 2000. Identification of a novel FGF, FGF21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203-206.
28. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M, Kuro-o M. 2007. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 104:7432-7437.
29. Ornitz DM, Itoh M. 2001. Fibroblast growth factors. Genome Biol 2:3005.
30. Presta M, Dell'Era P, Mitola E, Moroni E, Ronca R, Rusnati M. 2005. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-178.
31. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. 2002. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747.
32. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S, Imamura T. 2008. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22:1006-1014.
33. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774.
34. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koester A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. 2006. Fibroblast growth factor 21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase and Akt signaling pathways. Diabetes 55:2470-2478.
35. Wu X, Lemon B, Li X, Gupte J, Weiszmann J, Stevens J, Hawkins N, Shen W, Lindberg R, Chen JL, Tian H, Li Y. 2008. C-terminal Tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem 283:33304-33309.
36. Yu X, White KE. 2005. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 16:221-232.
37. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T. 2008. Anti-neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509-1518.
38. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. 2006. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281:11700-15694.
39. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. 2008. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-1253.